Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Applied Biology Inc
Better Life Pharmaceuticals Inc
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Dare Bioscience Inc
Emotiol Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
H. Lundbeck AS
Harrow Health Inc
Ivix Ltd
Kuhnil Pharmaceutical Co Ltd
M et P Pharma AG
Re-Pharm Ltd
S1 Biopharma Inc
TherapeuticsMD Inc
Female Sexual Dysfunction - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sildefil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estradiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKW-00GA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Sexual Dysfunction - Dormant Projects
Female Sexual Dysfunction - Discontinued Products
Female Sexual Dysfunction - Product Development Milestones
Featured News & Press Releases
Mar 09, 2020: Dare Bioscience presents positive Sildefil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
Dec 11, 2019: Dar? Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildefil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Cada
Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildefil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference
Oct 08, 2019: Mayfield Pharmaceuticals to Present update on lidocaine at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
Sep 24, 2019: TherapeuticsMD announces multiple presentations related to IMVEXXY at the 2019 Annual Meeting of the North American Menopause Society
Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101
Jun 17, 2019: Dar? Bioscience announces positive results in Thermography feasibility study with Sildefil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans
Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time
Mar 18, 2019: Dare Bioscience to present update on Sildefil Cream at 31st Annual ROTH Conference
Jan 04, 2019: S1 Biopharma announces expanded alysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting
Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder
Nov 29, 2018: Dare Bioscience announces initiation of content validity study for Sildefil Cream, 3.6%, a potential therapy for female sexual arousal disorder
Nov 27, 2018: Dare Bioscience Announces Enrollment in Thermography Feasibility Study with Sildefil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Female Sexual Dysfunction, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020


List of Tables


Number of Products under Development for Female Sexual Dysfunction, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Female Sexual Dysfunction - Pipeline by Applied Biology Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Better Life Pharmaceuticals Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2020
Female Sexual Dysfunction - Pipeline by EndoCeutics Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2020
Female Sexual Dysfunction - Pipeline by H. Lundbeck AS, H1 2020
Female Sexual Dysfunction - Pipeline by Harrow Health Inc, H1 2020
Female Sexual Dysfunction - Pipeline by Ivix Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2020
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H1 2020
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, H1 2020
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H1 2020
Female Sexual Dysfunction - Dormant Projects, H1 2020
Female Sexual Dysfunction - Dormant Projects, H1 2020 (Contd..1), H1 2020
Female Sexual Dysfunction - Discontinued Products, H1 2020